The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,775
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, MD
Howlader, N. (2011) · Medical Entomology and Zoology · Cited by 2,612
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa031644 · Cited by 2,335
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
Self-citationVinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., Cormier, Y., Goss, G., Inculet, R., Vallieres, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043623 · Cited by 1,810
DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
Olaussen, K. A., Dunant, A., Fouret, P., Brambilla, E., André, F., Haddad, V., Taranchon, E., Filipits, M., Pirker, R., Popper, H. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060570 · Cited by 1,727
Douillard, J.-Y., Rosell, R., De Lena, M., Carpagnano, F., Ramlau, R., Gonzáles-Larriba, J. L., Grodzki, T., Pereira, J. R., Le Groumellec, A., Lorusso, V., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70804-x · Cited by 1,573
Kim, E. S., Hirsh, V., Mok, T., Socinski, M. A., Gervais, R., Wu, Y.-L., Li, L.-Y., Watkins, C. L., Sellers, M. V., Lowe, E. S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61758-4 · Cited by 1,242
Jemal, A., Thun, M. J., Ries, L. A. G., Howe, H. L., Weir, H. K., Center, M. M., Ward, E., Wu, X.-C., Eheman, C., Anderson, R., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn389 · Cited by 957
Xu, Y., Liu, H., Chen, J., & Zhou, Q. (2010) · Thoracic Cancer · doi:10.1111/j.1759-7714.2010.00016.x · Cited by 884
Mechanism of Action of Antitumor Drugs that Interact with Microtubules and Tubulin
Jordan, M. (2012) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011023354290 · Cited by 775
DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in Xenografts
Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., & Potmesil, M. (1989) · Science · doi:10.1126/science.2555920 · Cited by 650
Giannakakou, P., Gussio, R., Nogales, E., Downing, K. H., Zaharevitz, D., Bollbuck, B., Poy, G., Sackett, D., Nicolaou, K. C., & Fojo, T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040546297 · Cited by 477
The Binding Mode of Epothilone A on α,ß-Tubulin by Electron Crystallography
Nettles, J. H., Li, H., Cornett, B., Krahn, J. M., Snyder, J. P., & Downing, K. H. (2004) · Science · doi:10.1126/science.1099190 · Cited by 421
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Xu, Y., & Villalona-Calero, M. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf337 · Cited by 413
Rosell, R., Danenberg, K. D., Alberola, V., Bepler, G., Sanchez, J. J., Camps, C., Provencio, M., Isla, D., Taron, M., Diz, P., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0156 · Cited by 352
Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer
Coley, H. M. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.01.007 · Cited by 351
Bepler, G., Kusmartseva, I., Sharma, S., Gautam, A., Cantor, A., Sharma, A., & Simon, G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1101 · Cited by 333
Tsao, M.-S., Aviel-Ronen, S., Ding, K., Lau, D., Liu, N., Sakurada, A., Whitehead, M., Zhu, C.-Q., Livingston, R., Johnson, D. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6953 · Cited by 325
Ceppi, P., Volante, M., Novello, S., Rapa, I., Danenberg, K. D., Danenberg, P. V., Cambieri, A., Selvaggi, G., Saviozzi, S., Calogero, R., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl300 · Cited by 323
Parker, R. J., Eastman, A., Bostick-Bruton, F., & Reed, E. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115080 · Cited by 299
ERCC1 Expression Is a Predictor of Survival in Resected Patients With Non-small Cell Lung Cancer
Simon, G. R., Sharma, S., Cantor, A., Smith, P., & Bepler, G. (2005) · Chest · doi:10.1378/chest.127.3.978 · Cited by 277
Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?
Sève, P., & Dumontet, C. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70029-9 · Cited by 274
Class III β-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non–Small Cell Lung Cancer
Gan, P. P., Pasquier, E., & Kavallaris, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0509 · Cited by 221
The role of β-tubulin isotypes in resistance to antimitotic drugs
Burkhart, C. A., Kavallaris, M., & Horwitz, S. B. (2001) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(00)00022-6 · Cited by 198
Rosell, R., Scagliotti, G., Danenberg, K. D., Lord, R. V., Bepler, G., Novello, S., Cooc, J., Crinò, L., Sánchez, J. J., Taron, M., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206419 · Cited by 188
Overview of Tumor Cell Chemoresistance Mechanisms
Gatti, L., & Zunino, F. (2005) · Chemosensitivity · doi:10.1385/1-59259-889-7:127 · Cited by 179
Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol
Kavallaris, M., Burkhart, C. A., & Horwitz, S. B. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690507 · Cited by 179
Simon, G., Sharma, A., Li, X., Hazelton, T., Walsh, F., Williams, C., Chiappori, A., Haura, E., Tanvetyanon, T., Antonia, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2099 · Cited by 179
Personalized Medicine and Inhibition of EGFR Signaling in Lung Cancer
Gazdar, A. F. (2009) · New England Journal of Medicine · doi:10.1056/nejme0905763 · Cited by 177
Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression
Rosell, R., Perez-Roca, L., Sanchez, J. J., Cobo, M., Moran, T., Chaib, I., Provencio, M., Domine, M., Sala, M. A., Jimenez, U., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005133 · Cited by 161
Chemoresistance in Non-Small Cell Lung Cancer
Sève, P., & Dumontet, C. (2005) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011053352604 · Cited by 149
Vansteenkiste, J., Lara, P. N., Chevalier, T. L., Breton, J.-L., Bonomi, P., Sandler, A. B., Socinski, M. A., Delbaldo, C., McHenry, B. M., Lebwohl, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7097 · Cited by 130
Andrews, P. A., Jones, J. A., Varki, N. M., & Howell, S. B. (1990) · Cancer Communications · doi:10.3727/095535490820874641 · Cited by 130
Boukovinas, I., Papadaki, C., Méndez, P., Tarón, M., Mavroudis, D., Koutsopoulos, A. V., Sanchez-Ronco, M., Sánchez, J. J., Trypaki, M., Staphopoulos, E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003695 · Cited by 128
Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies
Dumontet, C., Jordan, M. A., & Lee, F. Y. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0986 · Cited by 112
Microtubule Alterations and Mutations Induced by Desoxyepothilone B
Verrills, N. M., Flemming, C. L., Liu, M., Ivery, M. T. G., Cobon, G. S., Norris, M. D., Haber, M., & Kavallaris, M. (2003) · Chemistry & Biology · doi:10.1016/s1074-5521(03)00141-8 · Cited by 108
Dumontet, C., Isaac, S., Souquet, P.-J., Bejui-Thivolet, F., Pachéco, Y., Peloux, N., Frankfurter, A. J., Ludueña, R. F., & Pérol, M. (2005) · PubMed · Cited by 101
Vilmar, A. C., & Sørensen, J. B. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.08.006 · Cited by 101
Crul, M., van Waardenburg, R. C. A. M., Bocxe, S., van Eijndhoven, M. A. J., Pluim, D., Beijnen, J. H., & Schellens, J. H. M. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01508-3 · Cited by 92
Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer
Eckardt, J. R., Bentsion, D., Lipatov, O. N., Polyakov, I. S., MacKintosh, F. R., Karlin, D. A., Baker, G. S., & Breitz, H. B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3235 · Cited by 92
A Phase II Study of ABT-751 in Patients with Advanced Non-small Cell Lung Cancer
Mauer, A. M., Cohen, E. E. W., Ma, P. C., Kozloff, M. F., Schwartzberg, L. S., Coates, A., Qian, J. X., Hagey, A. E., & Gordon, G. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318174e01f · Cited by 90
Cellular Mechanisms of Resistance to Anthracyclines and Taxanes in Cancer: Intrinsic and Acquired
Chien, A. J., & Moasser, M. M. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.02.010 · Cited by 84
Belani, C. P., Brodowicz, T., Ciuleanu, T.-E., Kim, J. H., Krzakowski, M. J., Laack, E., Wu, Y.-L. L. C., Peterson, P. M., Krejcy, K., & Zielinski, C. C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.cra8000 · Cited by 83
Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment
Mimori, K., Sadanaga, N., Yoshikawa, Y., Ishikawa, K., HASHIMOTO, M., Tanaka, F., Sasaki, A., Inoue, H., Sugimachi, K., & Mori, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603182 · Cited by 79
Li, J., Li, Z., Du, Y., Li, X., Bao, Q., & Chen, P. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.078 · Cited by 69
Vilmar, A. C., Santoni‐Rugiu, E., & Sørensen, J. B. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq053 · Cited by 69
Mechanisms of Resistance to Camptothecins
Saleem, A., EDWARDS, T. K., Rasheed, Z. A., & Rubin, E. H. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb07024.x · Cited by 60
Brugger, W., Triller, N., Błasińska-Morawiec, M., Curescu, S., Sakalauskas, R., Manikhas, G., Mazières, J., Whittom, R., Rohr, K., & Cappuzzo, F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.8020 · Cited by 56
Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer
Tanaka, S., Nohara, T., Iwamoto, M., Sumiyoshi, K., Kimura, K., Takahashi, Y., & Tanigawa, N. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0877-5 · Cited by 49
Belani, C. P., Brodowicz, T., Ciuleanu, T., Kim, J. H., Krzakowski, M. J., Laack, E., Wu, Y. L., Peterson, P. M., Krejcy, K., & Zielinski, C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.cra8000 · Cited by 36
Schettino, C., Bareschino, M. A., Maione, P., Rossi, A., Ciardiello, F., & Gridelli, C. (2008) · Current Genomics · doi:10.2174/138920208784533665 · Cited by 24
Cited by
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance
Gupta, P. B., Pastushenko, I., Skibinski, A., Blanpain, C., & Kuperwasser, C. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.11.011 · Cited by 598
Rizvi, N. A., Hellmann, M. D., Brahmer, J. R., Juergens, R. A., Borghaei, H., Gettinger, S., Chow, L. Q., Gerber, D. E., Laurie, S. A., Goldman, J. W., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9861 · Cited by 445
Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence
Lin, S., Chang, C., Hsu, C., Tsai, M., Cheng, H., Leong, M. K., Sung, P., Chen, J., & Weng, C. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14816 · Cited by 425
The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer
Senthebane, D. A., Rowe, A., Thomford, N. E., Shipanga, H., Munro, D., Mazeedi, M. A. M. A., Almazyadi, H. A. M., Kallmeyer, K., Dandara, C., Pepper, M. S., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071586 · Cited by 399
Metadata
- Authors
- Chang, A.
- Venue
- Lung Cancer
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 71
- Issue
- 1
- Pages
- 3-10
- ISSN
- 0169-5002 (ISSN-L)
- OpenAlex
- W1993382872
- Cited by
- 443
- References
- 59
- FWCI
- 12.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.